ATHX Share Price

Open 1.88 Change Price %
High 1.89 1 Day -0.02 -1.08
Low 1.82 1 Week 0.00 0.00
Close 1.84 1 Month -0.33 -15.21
Volume 508843 1 Year 0.14 8.24
52 Week High 2.63
52 Week Low 1.02
ATHX Important Levels
Resistance 2 1.90
Resistance 1 1.88
Pivot 1.85
Support 1 1.80
Support 2 1.78
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%

Athersys, Inc. (NASDAQ: ATHX)

ATHX Technical Analysis 1.5
As on 31st Oct 2017 ATHX Share Price closed @ 1.84 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.58 & Sell for SHORT-TERM with Stoploss of 2.03 we also expect STOCK to react on Following IMPORTANT LEVELS.
ATHX Target for June
1st Target up-side 2.3
2nd Target up-side 2.63
3rd Target up-side 2.95
1st Target down-side 1.38
2nd Target down-side 1.05
3rd Target down-side 0.73
ATHX Other Details
Segment EQ
Market Capital 30027646.00
Sector Healthcare
Industry Biotechnology
Offical website
ATHX Address
3201 Carnegie Avenue
Cleveland, OH 44115
United States
Phone: 216-431-9900
Fax: 216-361-9495
ATHX Latest News
Interactive Technical Analysis Chart Athersys, Inc. ( ATHX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Athersys, Inc.
ATHX Business Profile
Athersys Inc., incorporated on October 24, 1995, is a biopharmaceutical company engaged in the field of regenerative medicine. During the year ended December 31, 2011 the Company is developing its platform product, MultiStem, a allogeneic stem cell product that has been evaluated in two completed Phase I clinical trials and as of December 31, 2011, is being evaluated in two ongoing Phase II clinical trials. The Company’s clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The Company is also engaged in the development of small molecule therapies to treat obesity and other conditions. During 2011, the Company is focused on the development of potent, highly selective compounds that act through stimulation of a specific receptor in the brain that controls appetite, the 5HT2c serotonin receptor. The Company is developing a non-embryonic, allogeneic stem cell product candidate, MultiStem. The applications of MultiStem, include the treatment of cardiovascular disease, neurological disease or injury and conditions involving the immune system, including autoimmune disease and other conditions. During 2011, the Company had open Investigational New Drug applications (INDs), for the study of MultiStem in distinct clinical indications. MultiStem is a biologic product that is manufactured from human stem cells obtained from adult bone marrow. The product consists of a special class of human stem cells that have the ability to express a range of therapeutically relevant proteins and other factors, as well as form multiple cell types. Another focus of the Company's regenerative medicine program is the use of MultiStem for the treatment of neurological injury as a result of acute or chronic conditions. During 2011, the Company is developing pharmaceutical treatments for obesity, which is a compound designed to act by stimulating a receptor in the brain that regulates appetite and food intake, the 5HT2c receptor. The role of this receptor in regulating food intake is well understood in both animal models and humans. The Company initiated a drug development program focused on creating potent and selective compounds that stimulate the 5HT2c receptor, but that avoid the 5HT2b receptor and other receptors, such as 5HT2a.